{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:32:14Z","timestamp":1790476334576,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004898","name":"EORTC Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004898","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.eururo.2014.05.033","type":"journal-article","created":{"date-parts":[[2014,6,16]],"date-time":"2014-06-16T17:03:10Z","timestamp":1402938190000},"page":"694-701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["The Effect of Age on the Efficacy of Maintenance Bacillus Calmette-Gu\u00e9rin Relative to Maintenance Epirubicin in Patients with Stage Ta T1 Urothelial Bladder Cancer: Results from EORTC Genito-Urinary Group Study 30911"],"prefix":"10.1016","volume":"66","author":[{"given":"Jorg R.","family":"Oddens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio A.","family":"Brausi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim J.","family":"Kirkels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees","family":"van de Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"van Andel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo M.","family":"de Reijke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Prescott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem","family":"Oosterlinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2014.05.033_bib0005","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.05.033_bib0010","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2013.06.003","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013","volume":"64","author":"Babjuk","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.05.033_bib0015","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non\u2013muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.05.033_bib0020","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.05.033_bib0025","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2014.05.033_bib0030","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ctrv.2009.12.005","article-title":"Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses","volume":"36","author":"Shelley","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2014.05.033_bib0035","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.05.033_bib0040","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","volume":"166","author":"van der Meijden","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.05.033_bib0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.urolonc.2007.04.005","article-title":"Effect of advanced age on the development of complications from intravesical bacillus Calmette-Gu\u00e9rin therapy","volume":"26","author":"Heiner","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1016\/j.eururo.2014.05.033_bib0050","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/BF01741551","article-title":"Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Gu\u00e9rin in superficial bladder cancer","volume":"34","author":"De Boer","year":"1992","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.eururo.2014.05.033_bib0055","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0022-5347(01)66424-3","article-title":"Urinary cytokines during intravesical bacillus Calmette-Gu\u00e9rin therapy for superficial bladder cancer: processing, stability and prognostic value","volume":"155","author":"de Reijke","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.05.033_bib0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1442-2042.2007.01696.x","article-title":"Intravesical instillation therapy with bacillus Calmette-Gu\u00e9rin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Gu\u00e9rin immunotherapy","volume":"14","author":"Shintani","year":"2007","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2014.05.033_bib0065","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0140-6736(74)91755-3","article-title":"Ageing, immune response, and mortality","volume":"2","author":"Roberts-Thomson","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2014.05.033_bib0070","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000156477","article-title":"Can the immune system still be efficient in the elderly? An immunological and immunoendocrine therapeutic perspective","volume":"15","author":"Pfister","year":"2008","journal-title":"Neuroimmunomodulation"},{"issue":"Suppl","key":"10.1016\/j.eururo.2014.05.033_bib0075","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/1097-0142(19950101)75:1+<316::AID-CNCR2820751314>3.0.CO;2-T","article-title":"Urinary system","volume":"75","author":"Lynch","year":"1995","journal-title":"Cancer."},{"key":"10.1016\/j.eururo.2014.05.033_bib0080","series-title":"TNM classification of malignant tumors (UICC)","year":"1997"},{"key":"10.1016\/j.eururo.2014.05.033_bib0085","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.05.033_bib0090","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2007.03.024","article-title":"Age and outcome of superficial bladder cancer treated with bacille Calmette-Gu\u00e9rin therapy","volume":"70","author":"Herr","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2014.05.033_bib0095","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/ijc.11352","article-title":"Urinary IL-2 assay for monitoring intravesical bacillus Calmette-Gu\u00e9rin response of superficial bladder cancer during induction course and maintenance therapy","volume":"107","author":"Saint","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2014.05.033_bib0100","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.urology.2011.04.070","article-title":"Diminished efficacy of Bacille Calmette-Gu\u00e9rin among elderly patients with nonmuscle invasive bladder cancer","volume":"78","author":"Margel","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2014.05.033_bib0105","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Gu\u00e9rin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.05.033_bib0110","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27mg) versus very low-dose bacillus Calmette-Guerin (13.5mg) versus mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.05.033_bib0115","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.05.033_bib0120","first-page":"135","article-title":"Bladder cancer in the elderly: clinical outcomes, basic mechanisms, and future research direction","volume":"6","author":"Taylor","year":"2009","journal-title":"Nat Clin Pract Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381400493X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228381400493X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:04:38Z","timestamp":1759583078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228381400493X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S030228381400493X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2014.05.033","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718458935.793498973","asserted-by":"object"}]},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Effect of Age on the Efficacy of Maintenance Bacillus Calmette-Gu\u00e9rin Relative to Maintenance Epirubicin in Patients with Stage Ta T1 Urothelial Bladder Cancer: Results from EORTC Genito-Urinary Group Study 30911","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2014.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}